<SEC-DOCUMENT>0001178913-25-001306.txt : 20250415
<SEC-HEADER>0001178913-25-001306.hdr.sgml : 20250415
<ACCEPTANCE-DATETIME>20250415080043
ACCESSION NUMBER:		0001178913-25-001306
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250415
FILED AS OF DATE:		20250415
DATE AS OF CHANGE:		20250415

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Chemomab Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				813676773
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		25837609

	BUSINESS ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002
		BUSINESS PHONE:		972-77-331-0156

	MAIL ADDRESS:	
		STREET 1:		KIRYAT ATIDIM, BUILDING 7
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			6158002

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Anchiano Therapeutics Ltd.
		DATE OF NAME CHANGE:	20180906

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk2533017.htm
<DESCRIPTION>6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><br style="line-height: 1.25;">
        </div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">UNITED STATES</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;"><font style="font-size: 14pt; font-family: 'Times New Roman',Times,serif;">SECURITIES AND EXCHANGE
          COMMISSION</font><br>
        Washington, D.C. 20549</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 14pt; font-weight: bold;">FORM 6-K</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16<br>
        UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">For the month of April 2025</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;">Commission File Number 001-38807</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25;"><font style="font-size: 16pt; font-family: 'Times New Roman',Times,serif; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</font><br>
        (Translation of registrant&#8217;s name into English)</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">Kiryat Atidim, Building 7, Tel-Aviv, Israel</div>
      <div style="text-align: center; line-height: 1.25;">(Address of principal executive offices)</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="line-height: 1.25;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>
      <div style="text-align: center; line-height: 1.25;">&#160;</div>
      <div style="text-align: center; line-height: 1.25; font-family: 'Times New Roman',Times,serif;">Form 20-F &#9746;&#160;&#160;&#160;&#160; Form 40-F &#9744;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXPLANATORY NOTE</div>
      <div style="line-height: 1.25;">&#160;</div>
      <div style="text-align: justify; line-height: 1.25;">On April 15, 2025, Chemomab Therapeutics Ltd. (&#8220;Chemomab&#8221; or the &#8220;Registrant&#8221;) announced the departure of its Chief Medical Officer,
        Dr. Matthew Frankel, and the appointment of Dr. David M. Weiner, MD, as Interim Chief Medical Officer, effective upon Dr. Frankel's departure on April 18, 2025. In addition, Chemomab has promoted Mr. Jack Lawler from his current position as Senior
        Vice President, Global Clinical Development Operations to Chief Development Officer. Chemomab issued a press release titled &#8220;Chemomab Announces New Medical and Clinical Appointments&#8221;. A copy of the press release is furnished as Exhibit 99.1
        herewith.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: justify; line-height: 1.25;">This Report of Foreign Private Issuer on Form 6-K and the press release attached as Exhibit 99.1 to this Report of Foreign Private
        Issuer on Form 6-K are hereby incorporated by reference into the Registrant&#8217;s Registration Statements on Form F-3 (File No. 333-275002 and 333-281750) and Form S-8 (File No. 333-259489 and No. 333-266868).</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">EXHIBIT INDEX</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z0cef1d51f01941faa82ac0baf3255f88" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div style="line-height: 1.25;"><u>Exhibit</u></div>
            </td>
            <td style="width: 90%; vertical-align: top;">
              <div style="line-height: 1.25;"><u>Description</u></div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 90%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 10%; vertical-align: top;">
              <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">99.1</a></div>
            </td>
            <td style="width: 90%; vertical-align: top;">
              <div style="line-height: 1.25;"><a href="exhibit_99-1.htm">Press release, dated
                  April 15, 2025, titled &#8220;Chemomab Announces New Medical and Clinical Appointments&#8221;</a></div>
            </td>
          </tr>

      </table>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="text-align: center; line-height: 1.25;">SIGNATURE</div>
      <div style="text-align: center; line-height: 1.25; font-weight: bold;">&#160;</div>
      <div style="text-align: justify; text-indent: 36pt; line-height: 1.25;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to
        be signed on its behalf by the undersigned, thereunto duly authorized.</div>
      <div style="line-height: 1.25;">&#160;</div>
      <table cellspacing="0" cellpadding="0" border="0" id="z86f36c484e114441bd79768fc5c37f16" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="vertical-align: top;" colspan="2">
              <div style="line-height: 1.25; font-weight: bold;">CHEMOMAB THERAPEUTICS LTD.</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 46%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">Date: April 15, 2025</div>
            </td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">By:</div>
            </td>
            <td nowrap="nowrap" style="width: 46%; vertical-align: top; border-bottom: 2px solid rgb(0, 0, 0);">
              <div style="line-height: 1.25;">/s/ Sigal Fattal</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td nowrap="nowrap" style="width: 46%; vertical-align: bottom;">
              <div style="line-height: 1.25;">Sigal Fattal</div>
            </td>
          </tr>
          <tr>
            <td style="width: 50%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 4%; vertical-align: top;">
              <div style="line-height: 1.25;">&#160;</div>
            </td>
            <td style="width: 46%; vertical-align: top;">
              <div style="line-height: 1.25;">Chief Financial Officer</div>
            </td>
          </tr>

      </table>
      <div> <br>
      </div>
      <div>
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: company
         Document created using Broadridge PROfile 25.2.1.5287
         Copyright 1995 - 2025 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;">
    <div style="text-align: right;"><u><font style="font-weight: bold;">Exhibit 99.1</font></u><br>
    </div>
    <div> <br>
    </div>
    <div>
      <div class="BRPFPageHeader">
        <div style="line-height: 1.25;"><img width="201" height="56" src="image00003.jpg"></div>
        <div style="line-height: 1.25">&#160;</div>
      </div>
      <div style="text-align: center; margin-right: 49.1pt; margin-left: 48.85pt; line-height: 1.25; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Chemomab Announces New Medical and Clinical Appointments</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="text-align: center; text-indent: -0.1pt; margin-right: 39.35pt; margin-left: 39.7pt; line-height: 1.25; font-style: italic;">David M. Weiner, MD, Rejoins Chemomab as Interim
        Chief Medical Officer, Bringing Extensive </div>
      <div style="text-align: center; text-indent: -0.1pt; margin-right: 39.35pt; margin-left: 39.7pt; line-height: 1.25; font-style: italic;">Biotechnology and Pharmaceutical Industry R&amp;D,
        Drug Development and Strategic Experience</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="text-align: center; margin-right: 49.1pt; margin-left: 49.1pt; line-height: 1.25; font-style: italic;">Jack Lawler, Who Oversaw the Conduct of Chemomab&#8217;s Successful Phase 2
        SPRING Trial in</div>
      <div style="text-align: center; margin-right: 48.85pt; margin-left: 49.1pt; line-height: 1.25; font-style: italic;">PSC, Assumes Chief Development Officer Role</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-right: 6.2pt; margin-left: 5pt; line-height: 1.25;"><font style="font-weight: bold;">TEL
          AVIV, Israel, April 15, 2025 </font>-- Chemomab Therapeutics, Ltd., (Nasdaq: CMMB), a
          clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that David M. Weiner, MD, has been named Interim Chief Medical Officer and Jack Lawler, Senior
        Vice President of Global Medical Operations at Chemomab, has been named Chief Development Officer. Dr. Weiner, who is based in the U.S., was Interim Chief Medical Officer (CMO) at Chemomab in 2021-2022 and has served as a consultant to the company
        in the years since. He has more than 25 years of experience in the discovery and clinical development of novel therapeutics and has held senior executive roles at private and public biotechnology companies. Dr. Weiner is replacing Matt Frankel, MD.
        Mr. Lawler joined Chemomab in 2022 and is also based in the U.S. He has 25 years of clinical drug development experience, including contributing to the development of eight approved pharmaceutical products across a variety of therapeutic
        indications.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-right: 6.85pt; margin-left: 5pt; line-height: 1.25;">&#8220;We are delighted that Dave Weiner is rejoining the company,&#8221; said Adi Mor, PhD, co-founder and
        Chief Executive Officer of Chemomab. &#8220;Dave has worked with Chemomab for a number of years and was a major contributor to the design of the clinical program that resulted in the successful nebokitug Phase 2 SPRING trial in primary sclerosing
        cholangitis (PSC). We anticipate a smooth transition with our PSC Phase 2 program now successfully completed and our planning for next steps underway. We also want to thank Matt Frankel for his contributions to our medical and clinical achievements
        and we wish him success in his future endeavors .&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-right: 6.85pt; margin-left: 5pt; line-height: 1.25;">Dr. Mor continued, &#8220;Jack Lawler has been instrumental in our clinical progress over the past
        three years. His leadership in building a first-rate U.S.-based clinical organization that successfully implemented a global PSC clinical program for nebokitug and delivered positive clinical results on budget and ahead of schedule has been
        invaluable. Jack also helped spearhead our efforts to build strong relationships with PSC opinion leaders, leading clinical centers and advocates worldwide that will serve us well going</div>
      <div style="margin-left: 5pt; line-height: 1.25;">forward.&#8221;</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-right: 7.95pt; margin-left: 5pt; line-height: 1.25;">Dr. Weiner commented, &#8220;I welcome the opportunity to rejoin Chemomab at this exciting time for the
        company. We have reported compelling clinical proof-of-concept data showing that nebokitug has the potential to become the first FDA-approved drug for PSC with disease-modifying activity and that it also may have potential in other
        fibro-inflammatory diseases. These are challenging times for our industry but with our experienced team and record of cost-effective scientific and clinical progress, I am optimistic we will realize the great medical, clinical and commercial
        potential of nebokitug. I look forward to working again with Jack, who I view as among the most effective clinical operations experts in our industry.&#8221;</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-right: 6.1pt; margin-left: 5pt; line-height: 1.25;">David Weiner has 30 years&#8217; experience in the discovery and development of novel therapeutics. He
        is currently Chief Scientific Officer and a director at AxoSIm, Inc. and a director at Bright Minds Biosciences and Novoron Bioscience. Previously he served in multiple leadership roles in neurology and rare disease- focused biotechnology
        companies, including as Interim Chief Medical Officer at Chemomab Therapeutics, as Chief Executive Officer of Amathus Therapeutics and as Chief Medical Officer at Lumos Pharma, aTyr Pharma and Proteostasis Therapeutics. Earlier in his career, Dr.
        Weiner held key drug development roles at EMD/Merck Serono and spent a decade in discovery research and clinical development at Acadia Pharmaceuticals. Dr. Weiner received a BA degree cum laude with highest honors from Brandeis University and an MD
        degree from the School of Medicine and Biomedical Sciences, SUNY Buffalo. He did a post-doctoral fellowship in neuropharmacology at the University of Vermont and was a Howard Hughes Medical Institute Research Scholar. Dr. Weiner has co-authored
        over 30 scientific publications and multiple patents. He serves as a director, consultant and scientific and clinical advisory board member to biotechnology companies and foundations, including the Michael J. Fox Foundation for Parkinson&#8217;s
        Research.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-right: 7.95pt; margin-left: 5pt; line-height: 1.25;">Prior to joining Chemomab, Jack Lawler served on the senior leadership team at Goldfinch Bio as
        Vice President, Clinical Operations and Data Management. Earlier, Mr. Lawler held a series of drug development positions of increasing responsibility at biopharmaceutical firms including Cephalon (acquired by Teva), Trevena, Viropharma (acquired by
        Shire), Botanix and Egalet. He participated in the successful development of numerous pharmaceutical products, including Cinqair<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, Provigil<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
        and Nuvigil<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>, among others. Earlier in his career, Mr. Lawler worked in emergency and transplant medicine. He earned a Bachelor of Science degree summa cum laude from Rosemont College.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div style="margin-left: 5pt; line-height: 1.25; font-weight: bold;">Forward-Looking Statements</div>
      <div style="margin-left: 5pt; line-height: 1.25;">This press release contains forward-looking statements within the meaning of the &#8220;safe harbor&#8221; provisions of the
        Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release, including statements regarding our future financial
        condition, results of operations, business strategy and plans, and objectives of management for future operations, as well as statements regarding industry trends, are forward-looking statements. In some cases, you can identify forward-looking
        statements by terminology such as &#8220;estimate,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;plan,&#8221; &#8220;potentially&#8221; &#8220;will&#8221; or the negative of these terms or other similar expressions. We have based these forward-looking statements largely on our current expectations and
        projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and
        assumptions, including, among other things: the risk that certain acknowledgements from the End-of-Phase 2 (EOP2) meeting with the FDA in connection with PSC regulatory approval will not materialize into a pathway for regulatory approval; that
        certain conclusions and assumptions drawn from the EOP2 meeting with the FDA discussed in the presentation will prove incorrect and adversely affect the ability for nebokitug to become an FDA fully approved therapy; the risk that the full data set
        from the nebokitug study or data generated in further clinical trials of nebokitug will not be consistent with the topline results of the nebokitug Phase 2 PSC trial; failure to obtain, or delays in obtaining, regulatory approvals for nebokitug in
        the U.S., Europe or other territories; failure to successfully commercialize nebokitug, if approved by applicable regulatory authorities, in the U.S., Europe or other territories, or to maintain U.S., European or other territory regulatory approval
        for nebokitug if approved; uncertainties in the degree of market acceptance of nebokitug by physicians, patients, third-party payors and others in the healthcare community; nebokitug development of unexpected safety or efficacy concerns related to
        nebokitug; failure to successfully conduct future clinical trials for nebokitug, including due to the Company's potential inability to enroll or retain sufficient patients to conduct and complete the trials or generate data necessary for regulatory
        approval, among other things; risks that the Company's clinical studies will be delayed or that serious side effects will be identified during drug development; failure of third parties on which the Company is dependent to manufacture sufficient
        quantities of nebokitug for commercial or clinical needs, to conduct the Company's clinical trials; changes in laws and regulations applicable to the Company's business and failure to comply with such laws and regulations; business or economic
        disruptions due to catastrophes or other events, including natural disasters or public health crises; and uncertainties with respect to the Company's need and ability to access future capital; and the intensity and duration of the current war in
        Israel, and its impact on our operations in Israel. These risks are not exhaustive. You should carefully consider the risks and uncertainties described in the &#8220;Risk Factors&#8221; sections of our 20-F for the year ended December 31, 2024. New risk
        factors emerge from time to time, and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual
        results to differ materially from those contained in, or implied by, any forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Except as required by law, we undertake no obligation to
        update publicly any forward-looking statements for any reason after the date of this press release. Before you invest, you should read the documents we have filed and will file with the SEC for more complete information about us. You may get these
        documents for free by visiting EDGAR on the SEC website at <u>www.sec.gov</u>.
        This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be
        unlawful prior to registration or qualification under the securities law of any such state or jurisdiction.</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 5pt; line-height: 1.25; font-weight: bold;">About Chemomab Therapeutics Ltd.</div>
      <div style="margin-right: 6.85pt; margin-left: 5pt; line-height: 1.25;">Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-
        inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed nebokitug (CM-101), a first-in-class dual activity monoclonal antibody that neutralizes
        CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, nebokitug has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and
        life-threatening fibro- inflammatory diseases. Chemomab has reported positive results from four clinical trials of nebokitug in patients. Based on positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company is
        preparing for potential initiation of a nebokitug PSC Phase 3 trial. The design of Phase 3 calls for a single pivotal trial based on a clinical event primary endpoint that provides a clear and streamlined pathway to potential full regulatory
        approval. Nebokitug has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab&#8217;s nebokitug program for the treatment of systemic sclerosis has an open U.S. IND. For more information, visit: <u>chemomab.com</u>.</div>
      <div style="line-height: 1.25">&#160;</div>
      <div style="margin-left: 5pt; line-height: 1.25; font-weight: bold;">Contacts:</div>
      <div style="line-height: 1.25;"><br style="line-height: 1.25;">
      </div>
      <div style="margin-left: 5pt; line-height: 1.25; font-weight: bold;">Media and Investors:</div>
      <div style="margin-left: 5pt; line-height: 1.25;">Barbara Lindheim</div>
      <div style="margin-right: 83.3pt; margin-left: 5pt; line-height: 1.25;">Consulting Vice President, Investor &amp; Public Relations, Strategic Communications </div>
      <div style="margin-right: 83.3pt; margin-left: 5pt; line-height: 1.25;">Phone: +1 917-355-9234</div>
      <div style="margin-right: 228.3pt; margin-left: 5pt; line-height: 1.25;"><u>barbara.lindheim@chemomab.com</u>&#160;</div>
      <div style="margin-right: 228.3pt; margin-left: 5pt; line-height: 1.25;"><u>IR@chemomab.com</u></div>
      <div style="margin-right: 228.3pt; margin-left: 5pt; line-height: 1.25;"><u> <br>
          </u></div>
      <div style="line-height: 1.25; font-family: 'Times New Roman',Times,serif;">
        <hr align="center" style="border: none; border-bottom: 4px solid black; border-top: 1px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"> </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image00003.jpg
<TEXT>
begin 644 image00003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !V :,# 2(  A$! Q$!_\0
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MAKPMHVI>(-?U>\?9:Z;I&D6DM]J%[.P!/EV]K!+*P56=MNU%9RJG^4S]J/\
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M,]K<P31.Z,LD9QG*D, 1_!-X"T.3_@AM_P '%/A?X*_#?5-0LOV7_P!JS6/
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M;SP^-SVNIWGCG1/!FC^%+=9;9H+F:6T2XLH=QCCNKB/;</\ L-_P21_X+S_
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MFK:_);PI->:QX1E\$ZSIUAJ#R?:)=/\ $3VMT\\6GZ:MK'#7^HG%&9T.%O\
M5:ME;S!5L-EN?0S?&XK,J6*C2G/#UL=AIN. K*LZ:C6IT:%*E"4[4U%?O(UF
MCSW*\+4S7^U88I89TZN)R^6#P]+#3HN<8U:="JD\33<%)RIRG5J2E;WKMV/T
M7_X*&_\ !Q3X#_9J^-NL_LI_L?\ P(\3?MG_ +1GAF_GT?QAI_A.75V\&>%-
M?M&6/4?#<+>%=$\2>)/&?B/1IG2VUO3]!T^WT[2KX2Z5=ZY'JMM>65M^;>G_
M /!U!^UW\$/'&A6/[:G_  3BUGX;^"]=O79O(MOB-\-/'$6E)@S7'AW2_BCH
M-OI/BFYM%>(M;27VB0S;P7U"T!&[];/^#<G]BCX>_L^_\$__ (8?M!7FB:=K
M/[0'[6&F7/Q>^(WQ,U&$:CXIN] \0ZMJ-QX&\,1:Y?>=J46E6?AO[#K&I6J3
MK'?>*=9US4KCSI)HF3](?^"DW[)'P[_;4_8Q^/7P3\>Z%I6HWFI_#GQ9JW@#
M7KW3XKS4/!/Q'T31+W5/!?BO1ICLN;:YTW7;6R-W':W$']I:8][I5TSVE[/&
MW*L;P!D^:RR#%<+SS?!X7%O+L?Q#6S7,,-F%:K3G]7Q>/P>"PTX82CAZ595*
MF$PTX5*E2A""Q%7VDY*.WL,_QN&CCZ6:QP56M26(P^70PF&K8>$91]I2H5Z]
M6,JU2<XN,:]6$H1C-R]E'EBG+VK]ES]I[X-_MC? WP+^T-\!?%,/BWX;^/\
M3GN],O1&;;4=,O[29[/6?#OB#37)GTCQ%H&I0W&FZQIEQ^\MKN!BC2V\D,\O
M6?&_XV_"_P#9R^%/CCXV_&;Q=IG@;X:?#O0[GQ!XJ\2ZK(5M[*R@*QQ000H'
MN+[4M1NY;?3M)TNSCFOM4U*ZM;"R@FN;B*-OX]_^#.3XN>)]2\%?MN_ N_O#
M/X0\(>(_@W\4?#%FQE9K#7/'FG^//"_C%DW.T2P7UIX \&LL4:1%9[6YE8RF
M<^73_P"#KO\ :"^(7Q'^+/[&_P#P35^%FH3?:_B7=Z-\4/%GAZ&XN;*#Q5XH
M\;^-+KX5?!'1]3NXI5MI=.L=9TWQOJ-SIUU!=1K?W.@:PR1SZ;9.V-7P_P"7
MQ&Q/!<<7*&"PV(E7K8^HHRG0RA8*&:2K56DJ?MXX*<:7,U"G+$N*<8QERJH<
M0J7#=+._8J=:I2C".'BW%5,8Z_U3V4+WER/$)M?%)4DW>5KOS/XB?\%M_P#@
MK-_P50^,WB+X+?\ !)#X/ZY\,/AIHUT(IOB##H7A_4_&T>CM=K##XA\?^/\
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M )+SAC_L91_],U3Z;BG_ ))_-/\ L&_]R0/V@_X(\?\ *+3]@?\ [-?^%/\
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M)*2_0\SGC(9?C)Y?%3QL:%1X:+2E>JEI:,O=E):N$97C*:2DFFT?SK_LL_\
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H$_WD9D59RE0PUW?VTJ<*FWO1FKR_PNZ3C*-I1^RT?>5%%%?/'H'_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
